Edition:
United Kingdom

Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

43.94USD
14 Dec 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$43.94
Open
$42.87
Day's High
$44.41
Day's Low
$42.87
Volume
78,261
Avg. Vol
100,964
52-wk High
$85.66
52-wk Low
$42.87

Latest Key Developments (Source: Significant Developments)

Eagle Pharmaceuticals Announces Positive Results Of Pre-Clinical Study Conducted To Evaluate Effects Of Ryanodex In Acute Radiation Syndrome (ARS)
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF PRE-CLINICAL STUDY CONDUCTED TO EVALUATE EFFECTS OF RYANODEX IN ACUTE RADIATION SYNDROME (ARS).EAGLE PHARMACEUTICALS INC - TO EXPLORE ARS INDICATION TO TREAT INDIVIDUALS EXPOSED TO HIGH DOSES OF RADIATION.EAGLE PHARMACEUTICALS INC - PLANS TO CONDUCT FURTHER RESEARCH FOR TREATMENT OF POST-IRRADIATION HEMATOPOIETIC SYNDROME.EAGLE PHARMACEUTICALS INC - RYANODEX TREATMENT GROUP HAD OVERALL LESS MORTALITY POST-TREATMENT THAN NON-TREATED ANIMALS WITH ARS.EAGLE PHARMACEUTICALS - ADDITIONAL RESEARCH ONGOING TO EVALUATE HEMATOPOIETIC SYNDROME IN CERTAIN CANCER PATIENTS UNDERGOING RADIATION THERAPY.  Full Article

Eagle Pharmaceuticals Inc Reports Q2 Adjusted Non-GAAP Earnings Per Share $0.95
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS, INC. REPORTS SECOND QUARTER 2018 RESULTS.Q2 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.95.Q2 EARNINGS PER SHARE $0.17.Q2 REVENUE $59.3 MILLION VERSUS I/B/E/S VIEW $51.2 MILLION.Q2 EARNINGS PER SHARE VIEW $0.80 -- THOMSON REUTERS I/B/E/S.REITERATING 2018 EXPENSE GUIDANCE.  Full Article

FDA Grants Eagle Seven Year Orphan Drug Exclusivity For BENDEKA (Bendamustine Hydrochloride Injection)
Monday, 9 Jul 2018 

July 9 (Reuters) - Eagle Pharmaceuticals Inc ::FDA GRANTS EAGLE SEVEN YEAR ORPHAN DRUG EXCLUSIVITY FOR BENDEKA (BENDAMUSTINE HYDROCHLORIDE INJECTION).FDA GRANTS EAGLE SEVEN YEAR ORPHAN DRUG EXCLUSIVITY FOR BENDEKA (BENDAMUSTINE HYDROCHLORIDE INJECTION).EAGLE PHARMACEUTICALS INC - FDA WILL NOT APPROVE ANY DRUG APPLICATIONS REFERENCING BENDEKA UNTIL ODE EXPIRES IN DECEMBER 2022.  Full Article

Eagle Pharmaceuticals Gets Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In 500Ml Admixture
Wednesday, 16 May 2018 

May 16 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS INC GRANTED FINAL FDA APPROVAL FOR BENDAMUSTINE HYDROCHLORIDE READY-TO-DILUTE SOLUTION IN A 500ML ADMIXTURE.SAYS EAGLE TO SHIP 500ML ADMIXTURE PRODUCT IMMEDIATELY.  Full Article

Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA
Monday, 16 Apr 2018 

April 16 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS’ VASOPRESSIN ANDA ACCEPTED FOR FILING BY THE FDA.EAGLE PHARMACEUTICALS INC - PRODUCT IS GENERIC VERSION OF ENDO INTERNATIONAL PLC'S ORIGINAL VASOSTRICT FORMULATION.  Full Article

Iridian Asset Management Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Iridian Asset Management::IRIDIAN ASSET MANAGEMENT REPORTS 10.1 PERCENT PASSIVE STAKE IN EAGLE PHARMACEUTICALS AS OF DEC 31, 2017 - SEC FILING‍​.  Full Article

Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS COMMENCES PIVOTAL STUDY FOR FULVESTRANT.EAGLE PHARMACEUTICALS- ANTICIPATES COMPLETION OF FULVESTRANT STUDY WITHIN TWELVE MONTHS, AND AN EXPECTED NDA FILING IN Q4 OF 2018.  Full Article

Eagle Pharmaceuticals Q3 earnings per share $0.98
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Eagle Pharmaceuticals Inc :Eagle Pharmaceuticals Inc reports third quarter 2017 results.Q3 adjusted non-GAAP earnings per share $1.22.Q3 earnings per share $0.98.Q3 revenue $63 million versus I/B/E/S view $51.9 million.Q3 earnings per share view $0.80 -- Thomson Reuters I/B/E/S.Expect full year 2017 research and development expense will be consistent with upper end of $31-$35 million range​.Plan to begin dosing patients in Fulvestrant study in a few weeks and expect to file an NDA in Q4 of 2018​.Expect full year 2017 SG&A expense to be in range of $67 million - $70 million, slightly higher than previous guidance​.Will continue purchasing up to an additional $100 million shares under current share repurchase plan​.On PEMFEXY, says "hope to find a way to market" as soon as possible, once co's litigation with Eli Lilly is resolved​.  Full Article

EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY (PEMETREXED INJECTION) READY-TO-DILUTE.EAGLE PHARMACEUTICALS INC - ‍FDA HAS GRANTED TENTATIVE APPROVAL FOR COMPANY'S PEMFEXY​.  Full Article